WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections[1][2].
WIN 54954 reduces plaque formation of 50 of 52 rhinovirus serotypes (MICs ranges from 0.007 to 2.2 μg/mL)[1].WIN 54954 inhibits 15 commonly isolated enteroviruses, with an EC80 of 0.06 μg/mL[1].
WIN 54954 (2-100 mg/kg; p.o.) protects 50% of the mice from developing paralysis following infection with coxsackievirus A-9 and echovirus-9 at the dose of 2 and 100 mg/kg, respectively[1].
[1]. Woods MG, et, al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74.
[2]. Fechner H, et, al. Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules. 2011 Oct 11;16(10):8475-503.